Vascular Biogenics Ltd. (NASDAQ:VBLT) : Average target price received by Vascular Biogenics Ltd. (NASDAQ:VBLT) is $16.6 with an expected standard deviation of $4.45. The most aggressive target on the stock is $22, whereas the most downbeat target is $11. 5 financial analysts are currently covering the stock.
Shares of Vascular Biogenics Ltd. rose by 9.5% in the last five trading days and 31.34% for the last 4 weeks. Vascular Biogenics Ltd. is up 35.59% in the last 3-month period. Year-to-Date the stock performance stands at -12.36%.
Vascular Biogenics Ltd. (NASDAQ:VBLT) : 5 brokerage houses believe that Vascular Biogenics Ltd. (NASDAQ:VBLT) is a Strong Buy at current levels. Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
Vascular Biogenics Ltd. (NASDAQ:VBLT): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.26 and $4.22 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.87. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.61, notching a gain of 11.08% for the day. The total traded volume was 3,201,211 . The stock had closed at $4.15 on the previous day.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Companys program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company is developing VB-111, the lead oncology product candidate from its VTS platform technology, which is a gene-based biologic for the treatment of solid tumor indications, with clinical programs in recurrent glioblastoma (rGBM), thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.